Evidence map›Paper›PMID 39425798›Full record

ArticleArchives of virology2024

Isolation and characterization of Yersinia phage fMtkYen3-01.

Sophia Goladze, Sheetal Patpatia, Henni Tuomala, Matti Ylänne, Nino Gachechiladze, Daniel de Oliveira Patricio, Mikael Skurnik, Lotta-Riina Sundberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Anti-infective compounds forSustainable microbiology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sophia GoladzeDepartment of Biological and Environmental Science and Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.ORCID http://orcid.org/0000-0002-1316-6996
Sheetal PatpatiaHuman Microbiome Research Program, Department of Bacteriology and Immunology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-7206-5394
Henni TuomalaHuman Microbiome Research Program, Department of Bacteriology and Immunology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0001-7404-7723
Matti YlänneHuman Microbiome Research Program, Department of Bacteriology and Immunology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-0832-6913
Nino GachechiladzeFaculty of Exact and Natural Sciences, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.ORCID http://orcid.org/0009-0007-3327-6563
Daniel de Oliveira PatricioDepartment of Biological and Environmental Science and Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.ORCID http://orcid.org/0000-0001-8318-3778
Mikael SkurnikHuman Microbiome Research Program, Department of Bacteriology and Immunology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0001-8791-9260
Lotta-Riina SundbergDepartment of Biological and Environmental Science and Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland. lotta-riina.sundberg@jyu.fi.ORCID http://orcid.org/0000-0003-3510-4398

Funding

Research Council of Finland #346772Shota Rustaveli National Science Foundation PHDF-21-2176
6 · The paper itself

Abstract

Yersinia enterocolitica causes yersiniosis, the third most common gastrointestinal infection in humans throughout Europe. The emergence of multidrug resistance and the lack of effective new antibiotics have drawn attention to phage therapy as a treatment option. Here, we report the complete genome sequence of phage fMtkYen3-01, which infects Y. enterocolitica serotype O:3 strains. This phage has a genome 40,415 bp in length with 45.1% GC content and 49 predicted genes. fMtkYen3-01 infected 9.5% of the 42 Y. enterocolitica strains tested and showed stability at 25-40 °C, as well as pH 5.0-10.0. These results suggest the therapeutic potential of this phage.

Indexed as

BacteriophagesGenome, ViralYersinia enterocoliticaBase CompositionHumansPhage TherapyYersinia Infections

Identifiers

PMID39425798
PMCPMC11490452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.